(Q44656784)

English

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

scientific article published on 21 December 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1 reference

based on heuristic

inferred from title

author name string

Dirk Strumberg

1

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Beate Schultheis

2

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

M E Scheulen

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

R A Hilger

4

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

J Krauss

5

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

N Marschner

6

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

F Lordick

7

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

F Bach

8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

D Reuter

9

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

L Edler

10

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

K Mross

11

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

publication date

21 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

1138-1143

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

https://scigraph.springernature.com/pub.10.1007/s10637-010-9619-8

0 references

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Pancreatic cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

ErbB receptors: from oncogenes to targeted cancer therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

ErbB-directed immunotherapy: antibodies in current practice and promising new agents

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9619-8

21 January 2018

EGFR-targeting monoclonal antibodies in head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Options for the treatment of gemcitabine-resistant advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR inhibition as a therapy for head and neck squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nimotuzumab: evidence of clinical benefit without rash

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21170759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9619-8

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44656784&oldid=2031011150"